The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Self-citationThe Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433
Self-citationHesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Self-citationMayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
Bertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Self-citationCYP induction-mediated drug interactions: in vitro assessment and clinical implications
Lin, J. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0277-7 · Cited by 264
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
FABER, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 250
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246
Rostami-Hodjegan, A., & Tucker, G. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 239
Levy, R. H., Thummel, K. E., Trager, W. F., Hansten, P. D., & Eichelbaum, M. F. (2000) · Cited by 208
PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
Wang, Y.-H., Jones, D. R., & Hall, S. D. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.259 · Cited by 200
Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H., & Maurel, P. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09239-9 · Cited by 196
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice
Greenblatt, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00118-8 · Cited by 188
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
Backman, J., Olkkola, K., Aranko, K., Himberg, J., & Neuvonen, P. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04266.x · Cited by 184
Huang, S.-M. (2004) · Applications of Pharmacokinetic Principles in Drug Development · doi:10.1007/978-1-4419-9216-1_10 · Cited by 181
TURPEINEN, M., TOLONEN, A., UUSITALO, J., JALONEN, J., PELKONEN, O., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.010 · Cited by 163
SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST
Walsky, R. L., Obach, R. S., Gaman, E. A., Gleeson, J.-P. R., & Proctor, W. R. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002766 · Cited by 163
Self-citationGaletin, A., Burt, H., Gibbons, L., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006874 · Cited by 160
Ito, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 151
Ito, K., Hallifax, D., Obach, R. S., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003715 · Cited by 149
Self-citationPlasma buspirone concentrations are greatly increased by erythromycin and itraconazole*
Kivistö, K. T., Lamberg, T. S., Kantola, T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90038-2 · Cited by 147
Brown, H. S., Ito, K., Galetin, A., & Houston, J. B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02483.x · Cited by 145
Ghanbari, F., Rowland‐Yeo, K., Bloomer, J. C., Clarke, S. E., Lennard, M., Tucker, G. T., & Rostami‐Hodjegan, A. (2006) · Current Drug Metabolism · doi:10.2174/138920006776359293 · Cited by 143
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Houston, J. B., & Tremaine, L. M. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.004 · Cited by 134
Self-citationKanamitsu, S.-I., Ito, K., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007509324428 · Cited by 130
Alderman, J. A., Preskorn, S., Greenblatt, D. J., Harrison, W. M., Penenberg, D. N., Allison, J., & Chung, M. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00008 · Cited by 121
Ripp, S. L., Mills, J. B., Fahmi, O. A., Trevena, K. A., Liras, J. L., Maurer, T. S., & de Morais, S. M. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010132 · Cited by 121
Venkatakrishnan, K., & Obach, R. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004077 · Cited by 120
Self-citationLü, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M., & Rodrigues, A. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1352 · Cited by 109
Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Durol, A. L. B., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200006010-00007 · Cited by 103
Melet, A., Assrir, N., Jean, P., López-García, M. P., Marques‐Soares, C., Jaouen, M., Dansette, P. M., Sari, M., & Mansuy, D. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00548-9 · Cited by 100
Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro
Polasek, T. M., Elliot, D. J., Lewis, B. C., & Miners, J. O. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071803 · Cited by 96
MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
Heydari, A., Yeo, K. R., Lennard, M. S., Ellis, S. W., Tucker, G. T., & Rostami‐Hodjegan, A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001180 · Cited by 96
Kanamitsu, S.-I., Ito, K., Green, C. E., Tyson, C. A., Shimada, N., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007572803027 · Cited by 94
McConn, D. J., Lin, Y. S., Allen, K. E., Kunze, K. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.10.1083 · Cited by 85
Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y., & Iga, T. (2001) · PubMed · Cited by 80
Biotransformation of caffeine by cDNA-expressed human cytochromes P-450
Ha, H. R., Follath, F., Chen, J., & Krähenbühl, S. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/bf00226333 · Cited by 59
Accumulation of caffeine in healthy volunteers treated with furafylline.
Tarrus, E., Camı́, J., Roberts, D., Spickett, R. G. W., Celdrán, E., & Segura, J. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03003.x · Cited by 59
Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism
Tateishi, T., Kumai, T., Watanabe, M., Nakura, H., Tanaka, M., & Kobayashi, S. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00914.x · Cited by 44
Caffeine metabolism in patients with chronic liver disease
Rodopoulos, N., Wisén, O., & Norman, A. (1995) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519509089618 · Cited by 24
Calvo, G., García‐Gea, C., Luque, A., Morte, A., Dal‐Ré, R., & Barbanoj, M. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125689.05091.c6 · Cited by 23
Turck, D., Schwarz, A., Höffler, D., Narjes, H., Nehmiz, G., & Heinzel, G. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050203 · Cited by 16
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
Grimm, S. W., Einolf, H. J., Hall, S. D., He, K., Lim, H.-K., Ling, K.-H. J., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026716 · Cited by 310
Self-citation
Metadata
- Authors
- Obach, R. S., Walsky, R. L., & Venkatakrishnan, K.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 35
- Issue
- 2
- Pages
- 246-255
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2122651109
- Cited by
- 460
- References
- 43
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.